Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Relapsed Glioblastoma (REGOMA)
NCT02926222Phase 2Completed
- Sponsor
- Istituto Oncologico Veneto
- Start
- Nov 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in glioblastoma multiforme (GBM) (2 arms), sponsored by Istituto Oncologico Veneto. Primary endpoint: Overall Survival at 18 months. Started Nov 2015; status: completed.
02
Drugs
regorafenib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT02926222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926222.